The continuum of advanced therapies for rheumatoid arthritis

Focus on JAK-1 inhibitors

In just 75 minutes, bring yourself up to speed on new advances in therapies for rheumatoid arthritis, with a focus on JAK-1 inhibitors.

Janus kinase (JAK-1) inhibitors belong to a class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic options of rheumatoid arthritis and other immune-mediated diseases.

Stay engaged in the material thanks to an innovative video format and interactive questions throughout.

Learning Objectives

At the end of this program, participants will be able to:

  • Recognize unmet needs through the review of rheumatoid arthritis (RA) treatment landscape.
  • Discuss the role of Janus Kinase (JAK) inhibitors in the management of rheumatoid arthritis through a better understanding of their pharmacology.
  • Apply knowledge on expected efficacy and of potential side effects to counsel patients and monitor therapy on newly available targeted synthetic therapy upadacitinib.

CCCEP Accreditation

This program is CCCEP accredited for 1.25 CEU.

  • CCCEP Number: 1549-2020-2992-I-P, expires July 22, 2021.
  • Presenters: Michael Boivin, BSc, Bsc Phm, RPh and Aaron Sihota, BSc, BSc Pharm, RPh

Registration Information

This course is complimentary. Click on the link below and register to start the webinar.

Sponsored Content

This course was not developed by the BCPhA and is paid advertisement. For advertising inquiries, please email